The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed them for 18 months.

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

These offerings are designed to streamline workflows for eye care professionals and enhance patient experience.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

Ambulatory surgical centers are freestanding health care facilities that specialize in providing surgical and diagnostic procedures, not requiring an overnight stay.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.

The Perimeter B-Series OCT system combines proprietary AI technology with optical coherence tomography, for use during breast-conserving surgeries.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, a first-in-class mitochondria-targeted investigational therapeutic.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

The authors commented that the patient’s "age, relative acute onset, and lack of medical history make this an atypical presentation.”

Maria Vittoria Cicinelli, MD, Denise Loya-Garcia, MD, PhD, and Vishal Raval, MD, were announced as the recipients and will receive a $3,000 honorarium.